Chikungunya Vaccine, Live (cvx 317) Side Effects
Medically reviewed by Drugs.com. Last updated on Apr 23, 2025.
Applies to chikungunya vaccine, live (cvx 317): parenteral injection solution.
Important warnings
This medicine can cause some serious health issues
The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are recommending a pause in the use of Ixchiq (Chikungunya Vaccine, Live) in individuals 60 years of age and older while the Agencies investigate postmarketing reports of serious adverse events, including neurologic and cardiac events, in individuals who have received the vaccine.
For additional information see the FDA safety communication at [Web]
Side effects include:
Most common solicited injection site reaction (>10%) was tenderness (10.6%). Most common solicited systemic adverse reactions (>10%) were headache (31.6%), fatigue (28.5%), myalgia (23.9%), arthralgia (17.2%), fever (13.5%), and nausea (11.2%).
See also:
For healthcare professionals
Applies to chikungunya vaccine, live (cvx 317): intramuscular powder for injection.
General adverse events
The most commonly reported side effects included headache, fatigue, myalgia, and arthralgia.[Ref]
Cardiovascular
- Uncommon (0.1% to 1%): Peripheral edema, atrial fibrillation, severe atrial fibrillation
- Frequency not reported: Tachycardia[Ref]
Dermatologic
- Common (1% to 10%): Rash
- Uncommon (0.1% to 1%): Hyperhidrosis, erythematous rash
- Frequency not reported: Severe rash[Ref]
Gastrointestinal
- Very common (10% or more): Nausea (up to 11.2%)
- Common (1% to 10%): Vomiting, diarrhea
- Frequency not reported: Severe nausea, severe vomiting[Ref]
Hematologic
- Very common (10% or more): Grade 1 abnormal neutrophil results (up to 27.6%) grade 1 abnormal leukocyte results (up to 27.3%), grade 1 abnormal lymphocyte results (up to 19.1%), grade 2 abnormal neutrophil results (up to 11.3%)
- Common (1% to 10%): Grade 2 abnormal leukocyte results, grade 3 abnormal neutrophil results, grade 2 abnormal lymphocyte results
- Uncommon (0.1% to 1%): Grade 3 abnormal leukocyte results, grade 4 abnormal neutrophil results, grade 3 abnormal lymphocyte results, lymphadenopathy[Ref]
Immunologic
- Uncommon (0.1% to 1%): Influenza-like illness
- Frequency not reported: Chikungunya-like adverse reactions[Ref]
Local
- Very common (10% or more): Injection site tenderness (up to 10.6%)
- Common (1% to 10%): Injection site pain, injection site erythema/redness (at least 2.5 cm), injection site induration (at least 2.5 cm)
- Uncommon (0.1% to 1%): Injection site swelling (at least 2.5 cm)
- Rare (0.01% to 0.1%): Severe injection site pain
- Frequency not reported: Severe injection site tenderness[Ref]
Metabolic
- Frequency not reported: Hypovolemic hyponatremia, increased brain natriuretic peptide[Ref]
Musculoskeletal
- Very common (10% or more): Myalgia/muscle pain (up to 23.9%), arthralgia (up to 17.2%)
- Common (1% to 10%): Chills, back pain
- Uncommon (0.1% to 1%): Severe myalgia/muscle pain, severe arthralgia/joint pain, severe back pain
- Frequency not reported: Mild arthralgia, increased troponin, arthritis[Ref]
Nervous system
- Very common (10% or more): Headache (up to 31.6%)
- Uncommon (0.1% to 1%): Severe headache, dizziness, paresthesia, ataxia, hypoesthesia, peripheral neuropathy, syncope
- Frequency not reported: Prolonged arthralgia, polyarthralgia, nodular swelling of joints in fingers and foot[Ref]
Other
- Very common (10% or more): Fatigue (up to 28.1%), fever/pyrexia (up to 13.5%)
- Common (1% to 10%): Pain
- Uncommon (0.1% to 1%): Severe fatigue, severe/worse fever, asthenia, feeling abnormal
- Frequency not reported: Prolonged fatigue, severe fever[Ref]
Respiratory
- Frequency not reported: Tachypnea[Ref]
References
1. (2023) "Product Information. Ixchiq (cvx 317) (chikungunya vaccine, live (cvx 317))." Valneva USA
More about chikungunya vaccine, live (cvx 317)
- Check interactions
- Compare alternatives
- Latest FDA alerts (1)
- Dosage information
- During pregnancy
- Drug class: viral vaccines
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Chikungunya vaccine, live (cvx 317) side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.